ASH 2022 | Enduring responses following cevostamab therapy in R/R multiple myeloma
Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, comments on the duration of response (DOR) in a subset of patients with relapsed refractory (R/R) multiple myeloma, who came off of therapy with the bispecific T-cell engager (BiTE) cevostamab (NCT03275103). The majority of those that finished all 17 cycles of therapy had ongoing responses at nine months and, at 11 months, the majority of those who discontinued treatment because of adverse events continued to have responses. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer, Genmab, Sanofi, Iteos, BMS, Janssen: Consultancy; Memorial Sloan Kettering Cancer Center: Current Employment; Janssen, Pfizer, BMS, Genentech/Roche: Research Funding; Janssen, Pfizer, Iteos, Sanofi, Genmab: Honoraria; Serametrix, inc: Patents & Royalties; Trillium Therapeutics: Consultancy, Research Funding; Sanofi: Research Funding; BMS: Honoraria; Amgen: Honoraria.
